No dose-limiting toxicities, severe adverse events, or on-target off-tumor toxicities across all dose cohorts Deep and durable response observed in gastroesophageal cancer EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR™ platform and SCL mRNA…